Abstract:Background Intestinal ischemia/reperfusion injury (IRI) is a significant clinical emergency, and investigating novel therapeutic approaches and understanding their underlying mechanisms is essential for improving patient outcomes. Naringenin (Nar), a flavanone present in tomatoes and citrus fruits, is frequently consumed in the human diet and recognized for having immunomodulatory, anti-inflammatory, and antioxidant properties. Despite Nar being able to alleviate intestinal IRI, the exact molecular mechanisms remain elusive. Purpose To investigate Nar's protective properties on intestinal IRI and elucidate the mechanisms, a comprehensive approach that combines network pharmacology analysis with experimental verification in vitro and in vivo was adopted. Methods The oxygen-glucose deprivation/reoxygenation (OGD/R) model in IEC-6 cells and a murine model of intestinal IRI were used. Nar's effects on intestinal IRI were assessed through histological analysis using H&E staining and tight junction (TJ) protein expression. Ferroptosis-related parameters, including iron levels, superoxide dismutase (SOD), glutathione (GSH), reactive oxygen species (ROS), malondialdehyde (MDA), and mitochondrial morphology, were analyzed. Network pharmacology was utilized to predict the pathways through which Nar exerts its anti-ferroptosis effects. Further mechanistic insights were obtained through si-RNA transfection, YAP inhibitor (verteporfin, VP) treatment, ferroptosis inhibitor (Ferrostatin-1) and ferroptosis inducer (Erastin) application, co-immunoprecipitation (Co-IP) and Western blotting. Results Our results revealed that pretreatment with Nar significantly mitigated intestinal tissue damage and improved gut barrier function, as evidenced by increased TJ proteins (ZO-1 and Occludin). Nar reduced iron, MDA, and ROS, while it increased GSH and SOD levels. Additionally, Nar alleviated mitochondrial damage in mice. Nar treatment increased GPX4 and SLC7A11, while decreasing ACSL4 levels both in vivo and in vitro. Network pharmacology analysis suggested that Nar may target the Hippo signaling pathway. Notably, YAP, a key transcriptional co-activator within the Hippo pathway, was downregulated in intestinal IRI mice and OGD/R-induced IEC-6 cells. Nar pretreatment activated YAP, thereby augmenting anti-ferroptosis effects. The inhibition of YAP activation by VP or YAP knockdown increased p-STAT3 expression, thereby diminishing Nar's efficacy. Co-IP and immunofluorescence studies confirmed the interaction between YAP and STAT3. Conclusion This study shows that Nar can inhibit ferroptosis in intestinal IRI via activating YAP, which in turn suppresses STAT3 phosphorylation, thereby unveiling a novel mechanism and supporting Nar's potential to be a promising therapeutic agent for intestinal IRI.

Naringenin Exerts Anti-Angiogenic Effects in Human Endothelial Cells: Involvement of Err Alpha/Vegf/Kdr Signaling Pathway

Naringenin exerts anti-angiogenic effects in human endothelial cells: Involvement of ERRα/VEGF/KDR signaling pathway.

Naringenin Protects Against Septic Cardiomyocyte Injury Via PI3K- AKT Signaling Pathway

Naringin Inhibits Vascular Endothelial Cell Apoptosis Via Endoplasmic Reticulum Stress‑ and Mitochondrial‑mediated Pathways and Promotes Intraosseous Angiogenesis in Ovariectomized Rats.

Naringin inhibits autophagy mediated by PI3K-Akt-mTOR pathway to ameliorate endothelial cell dysfunction induced by high glucose/high fat stress

Naringin Protects Endothelial Cells from Apoptosis and Inflammation by Regulating the Hippo-YAP Pathway

Naringenin ameliorates homocysteine induced endothelial damage via the AMPKα/Sirt1 pathway

Naringenin alleviates intestinal ischemia/reperfusion injury by inhibiting ferroptosis via targeting YAP/STAT3 signaling axis

Heat Shock Protein 70 Mediates the Protective Effect of Naringenin on High-Glucose-Induced Alterations of Endothelial Function

Naringenin Inhibits Vascular Smooth Muscle Cell Function Involving Reactive Oxygen Species Production Modulation and NF- B Activity Suppression

Naringenin inhibits TNF-α induced VSMC proliferation and migration via induction of HO-1.

A novel compound, NP-184, inhibits the vascular endothelial growth factor induced angiogenesis.

Exploring the effects of naringin on oxidative stress-impaired osteogenic differentiation via the Wnt/β-catenin and PI3K/Akt pathways

Naringin Inhibits Growth Potential of Human Triple-Negative Breast Cancer Cells by Targeting Β-Catenin Signaling Pathway

The Anti-Atherosclerotic Effect of Naringin Is Associated with Reduced Expressions of Cell Adhesion Molecules and Chemokines through NF-κB Pathway

Naringin Enhances Endothelial Progenitor Cell (EPC) Proliferation and Tube Formation Capacity Through the CXCL12/CXCR4/PI3K/Akt Signaling Pathway.

Distinct Effects of Naringenin and Hesperetin on Nitric Oxide Production from Endothelial Cells.

Naringenin inhibits migration of breast cancer cells via inflammatory and apoptosis cell signaling pathways

Naringenin inhibits angiotensin II-induced vascular smooth muscle cells proliferation and migration and decreases neointimal hyperplasia in balloon injured rat carotid arteries through suppressing oxidative stress.

Network pharmacology combined with experimental verification to explore the potential mechanism of naringenin in the treatment of cervical cancer

Naringin Ameliorates Experimental Diabetic Renal Fibrosis by Inhibiting the ERK1/2 and JNK MAPK Signaling Pathways